Professional Documents
Culture Documents
XXX DAYTONA
XXX _OCEANSIDE
HEALTH CARE PARTNERS
Department:
Policy Number
PHARMACY
1000.519
Title:
HIGH-ALERT / HIGH-RISK /
HAZARDOUS / LOOK ALIKE /
SOUND ALIKE MEDICATIONS
Effective Date
10/10
Distribution:
PHARMACY,
FOOD & NUTRITION,
NURSING
3/05
APPROVALS:
Director
Date
Michele Goeb-Burkett
10/10
Vice President
Date
President/CEO
Date
Originated Date
1/06, 4/06, 8/06 , 9/06,
9/07, 7/08, 12/08, 9/09,
7/10, 9/10, 10/10
Revised Date
11/05
Reviewed Date
PURPOSE:
To identify medications with high risk to patients and provide a process to safely deliver these
medications to the patient.
GENERAL STATEMENT:
High Alert/High Risk medications are those listed and will be safely administered to the patient
through use of the verification process. Look alike, sound alike medications may also lead to
harmful medication errors. Steps will be taken to identify and warn of similarities to reduce chance
of confusion. Hazardous medications are those used for chemotherapy, antiviral drugs, hormones,
some bioengineered drugs and others that may cause toxicity.
SPECIFICS:
High Alert/High Risk medications are verified by two licensed professionals prior to administration.
This policy does not apply to licensed independent practitioners.
Verification includes independent visual confirmation of the physicians order and the following:
1.
2.
3.
4.
5.
Right patient using two identifiers (neither shall be the patient room number). This is
the responsibility of the nurse administering the medication.
Right medication(s)
Right route
Right dose/infusion rate/pump setting
Right time
Page 1 of 7
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
1.
2.
3.
4.
Pyxis Alert is defined as a reminder message that appears prior to obtaining a medication from the
pyxis machine as follows:
High Alert/High Risk Medication Verify Dose/Pump Settings.
High Alert/High Risk Medications in the pharmacy are indicated by a highlighted Red Label or
placement in a High Alert area designated by red (i.e. chemotherapy) or by indication on the label
generated by Talyst. The list of meds includes but is not limited to the following medications:
Methotrexate 2.5mg
Methotrexate 1Gm vials
Coumadin
Heparin all strengths
Heparin 25,000 Units/500ml
Magnesium 1 Gm/100ml
Lidociane 2 Gm 4mg/ml in D5
500ml
Potassium 20mEq/100ml
Potassium 10mEq/50ml
1.
2.
3.
4.
5.
Nitropress 50mg
Magnesium 1mg/2ml
Sodium chloride 23.4% 30ml
Potassium Phosphate 15ml
LASA medications listed are selected from the ISMP list of confused drug names, for error
reports, or medications with significant potential for harm. LASA are reviewed on an ongoing
basis and revised as needed. A review is performed at least annually.
CONCENTRATED ELECTROLYTES
Concentrated electrolytes are not stored or dispensed to any patient care area. Only
Magnesium Sulfate 1 Gm vials for IM use and crash care(with proper label and
instructions) are allowed outside the pharmacy.
HAZARDOUS MEDICATIONS
Hazardous medications as defined by ASHP and NIOSH include those that exhibit
one or more of the following:
a.
Carcinogenicity
b.
Teratogenicity or other developmental toxicity
c.
Reproductive toxicity
d.
Organ toxicity at low doses
e.
Genotoxicity
f.
Structure and toxicity profiles of new drugs that mimic existing drugs
determined hazardous by the above criteria
See attached the list of hazardous drugs as listed in the NIOSH Alert Preventing
Occupational Exposure to Antineoplastic and Other Hazardous Drugs in Health Care
Settings.
1.
2.
Source
Aldesleukin
4,5
Alemtuzumab
1,3,4,5
Alitretinoin
3,4,5
Altretamine
1,2,3,4,5
Amsacrine
3,5
Anastrozole
1,5
Arsenic trioxide
1,2,3,4,5
Asparaginase
1,2,3,4,5
Azacitidine
3,5
Azathioprine
2,3,5
Bacillus Calmette-Guerin
1,2,4
80:12 Vaccines
Bexarotene
2,3,4,5
Bicalutamide
1,5
Bleomycin
1,2,3,4,5
Busulfan
1,2,3,4,5
Capecitabine
1,2,3,4,5
Carboplatin
1,2,3,4,5
Carmustine
1,2,3,4,5
Cetrorelix acetate
Chlorambucil
1,2,3,4,5
Chloramphenicol
1,5
8:12 Antibiotics
Choriogonadotropin alfa
68:18 Gonadotropins
Cidofovir
3,5
8:18 Antivirals
Cisplatin
1,2,3,4,5
Cladribine
1,2,3,4,5
Colchicine
1,2,3,4,5
Cytarabine
1,2,3,4,5
Cyclosporin
Dacarbazine
1,2,3,4,5
Dactinomycin
1,2,3,4,5
Daunorubicin HCl
1,2,3,4,5
Denileukin
3,4,5
Dienestrol
68:16.04 Estrogens
Diethylstilbestrol
Dinoprostone
76:00 Oxytocics
Docetaxel
1,2,3,4,5
Doxorubicin
1,2,3,4,5
Dutasteride
Epirubicin
1,2,3,4,5
Ergonovine/methylergonovine
76:00 Oxytocics
Estradiol
1,5
68:16.04 Estrogens
1,2,3,4,5
Estramustine phosphate
sodium
Estrogen-progestin combinations 5
68:12 Contraceptives
Estrogens, conjugated
68:16.04 Estrogens
Estrogens, esterified
68:16.04 Estrogens
Estrone
68:16.04 Estrogens
Estropipate
68:16.04 Estrogens
Etoposide
1,2,3,4,5
Exemestane
1,5
Finasteride
1,3,5
Floxuridine
1,2,3,4,5
Fludarabine
1,2,3,4,5
Fluorouracil
1,2,3,4,5
Fluoxymesterone
68:08 Androgens
Flutamide
1,2,5
Fulvestrant
Ganciclovir
1,2,3,4,5
8:18 Antiviral
Ganirelix acetate
Gemcitabine
1,2,3,4,5
Gemtuzumab ozogamicin
1,3,4,5
Gonadotropin, chorionic
68:18 Gonadotropins
Goserelin
1,2,5
Hydroxyurea
1,2,3,4,5
Ibritumomab tiuxetan
Idarubicin
1,2,3,4,5
Ifosfamide
1,2,3,4,5
Imatinib mesylate
1,3,4,5
Interferon alfa-2a
1,2,4,5
1,2,4,5
Interferon alfa-n1
1,5
Interferon alfa-n3
1,5
Irinotecan HCl
1,2,3,4,5
Leflunomide
3,5
Letrozole
1,5
Leuprolide acetate
1,2,5
Lomustine
1,2,3,4,5
Mechlorethamine
1,2,3,4,5
Megestrol
1,5
Melphalan
1,2,3,4,5
Menotropins
68:18 Gonadotropins
Mercaptopurine
1,2,3,4,5
Methotrexate
1,2,3,4,5
Methyltestosterone
68:08 Androgens
Mifepristone
76:00 Oxytocics
Mitomycin
1,2,3,4,5
Mitotane
1,4,5
Mitoxantrone HCl
1,2,3,4,5
Mycophenolate mofetil
1,3,5
Nafarelin
68:18 Gonadotropins
Nilutamide
1,5
Oxaliplatin
1,3,4,5
Oxytocin
76:00 Oxytocics
Paclitaxel
1,2,3,4,5
Pegaspargase
1,2,3,4,5
Pentamidine isethionate
1,2,3,5
Pentostatin
1,2,3,4,5
Perphosphamide
3,5
Pipobroman
3,5
Piritrexim isethionate
3,5
Plicamycin
1,2,3,5
Podoflilox
Podophyllum resin
Prednimustine
3,5
Procarbazine
1,2,3,4,5
Progesterone
68:32 Progestins
Progestins
68:12 Contraceptives
Raloxifene
Raltitrexed
Ribavirin
1,2,5
8:18 Antiviral
Streptozocin
1,2,3,4,5
1,5
Tamoxifen
1,2,5
Temozolomide
3,4,5
Teniposide
1,2,3,4,5
Testolactone
1,2,3,4,5
Testosterone
68:08 Androgens
Thalidomide
1,3,5
Thioguanine
1,2,3,4,5
Thiotepa
1,2,3,4,5
Topotecan
1,2,3,4,5
Toremifene citrate
1,5
Tositumomab
3,5
Tretinoin
1,2,3,5
Trifluridine
1,2,5
52:04.06 antivirals
Trimetrexate glucuronate
Triptorelin
Uracil mustard
3,5
Valganciclovir
1,3,5
8:18 Antiviral
Valrubicin
1,2,3,5
Vidarabine
1,2,5
52:04.06 Antivirals
Vinblastine sulfate
1,2,3,4,5
Vincristine sulfate
1,2,3,4,5
Vindesine
1,5
Vinorelbine tartrate
1,2,3,4,5
Zidovudine
1,2,5
*
These lists of hazardous drugs were used with the permission of the institutions that provided them and were adapted for use by NIOSH. The sample lists are
intended to guide health care providers in diverse practice settings and should not be construed as complete representations of all of the hazardous drugs
used at the referenced institutions. Some drugs defined as hazardous may not pose a significant risk of direct occupational exposure because of their dosage
formulation (for example, intact medications such as coated tablets or capsules that are administered to patients without modifying the formulation). However,
they may pose a risk if solid drug formulations are altered outside a ventilated cabinet (for example, if tablets are crushed or dissolved, or if capsules are
pierced or opened).
The NIH Health Clinical Center Hazardous Drug (HD) List is part of the NIH Clinical Centers hazard communication program. It was developed in compliance
with the OSHA hazard communication standard [29 CFR 1910.1200] as it applies to hazardous drugs used in the workplace. The list is continually revised and
represents the diversity of medical practice at the NIH Clinical Center; however, its content does not reflect an exhaustive review of all FDA-approved
medications that may be considered hazardous, and it is not intended for use outside the NIH.
2
The University of Michigan Hospitals and Health Centers, Ann Arbor, MI (Revised 2/2003).
This sample listing of hazardous drugs was compiled by the Pharmaceutical Research and Manufacturers of America (PhRMA) using information from the
AHFS DI monographs published by ASHP in selected AHFS Pharmacologic-Therapeutic Classification categories [ASHP/AHFS DI 2003] and applying the
definition for hazardous drugs. The list also includes drugs from other sources that satisfy the definition for hazardous drugs [PDR 2004; Sweetman 2002;
Shepard 2001; Schardein 2000; REPROTOX 2003]. Newly approved drugs that have structures or toxicological profiles that mimic the drugs on this list should
also be included. This list was revised in June 2004.